Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Rank in Stocks #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Share Price
$1.48
Last synced: 2023-05-31
Market Cap
$35.54M
Change (1 day)
-5.73%
Change (1 year)
0.00%
Country
US
Trade TCR2 Therapeutics Inc. (TCRR)

Category

Stock price history for TCR2 Therapeutics Inc. (TCRR)
Highest end of day price: $1.83 on 2023-05-01

Lowest end of day price: $16.51 on 2019-02-01
Stock price history of TCR2 Therapeutics Inc. from 2019 to 2026
Annual Stock Price Performance
Year Performance
2023 73.43%
2022 -78.52%
2021 -83.60%
2020 79.84%
2019 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$120.74 -14.98%
AU
$758.75 6.61%
CH